Interleukin-3 - Novartis

Drug Profile

Interleukin-3 - Novartis

Alternative Names: Hemokine; ILE 964; Interleukin-3 - Sandoz; Muplestim; SDZ ILE 964

Latest Information Update: 12 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin 3 stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hodgkin's disease; Myeloid leukaemia; Non-Hodgkin's lymphoma; Thrombocytopenia

Most Recent Events

  • 12 Sep 2006 Discontinued - Phase-II for Myeloid leukaemia in Netherlands (IV-infusion)
  • 12 Sep 2006 Discontinued - Phase-II for Thrombocytopenia in Japan (Infusion)
  • 12 Sep 2006 Discontinued - Phase-III for Hodgkin's disease in European Union (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top